Early real-world experience with intravitreal Faricimab for neovascular AMD: FAN study

AJO International Pub Date : 2024-10-12 DOI:10.1016/j.ajoint.2024.100074

Constance Weber , Pascal Schipper , Isabel Stasik , Leonie Weinhold , Louisa Bulirsch , Sarah Thiele , Frank Holz , Raffael Liegl

{"title":"Early real-world experience with intravitreal Faricimab for neovascular AMD: FAN study","authors":"Constance Weber , Pascal Schipper , Isabel Stasik , Leonie Weinhold , Louisa Bulirsch , Sarah Thiele , Frank Holz , Raffael Liegl","doi":"10.1016/j.ajoint.2024.100074","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>This study presents real-world experiences and clinical outcomes of patients who switched to faricimab after prior treatment with other anti-vascular endothelial growth factor medication for patients with neovascular age-related macular degeneration (nAMD) in 2022.</div></div><div><h3>Design</h3><div>We evaluated all consecutive patients that received an intravitreal injection (IVI) with faricimab for nAMD and had complete follow-up visits after at least three IVI.</div></div><div><h3>Methods</h3><div>Functional and structural parameters including best-corrected visual acuity (BCVA, logMAR), foveal centre point (FCP, µm), central subfield retinal thickness (CSRT, µm) and macular volume (mm<sup>3</sup>) were evaluated after three (<em>n</em> = 71) and five (<em>n</em> = 57) faricimab injections with complete follow-up visits.</div></div><div><h3>Results</h3><div>We included 71 eyes of 63 patients. Mean BCVA at baseline was 0.49 logMAR (0 – 1.6) and did not change significantly after five faricimab injections (<em>p</em> = 0.33). Significant reductions were seen for FCP, CSRT and macular volume after the first five consecutive injections when compared to baseline (<em>p</em> < 0.0001 respectively). FCP was 388.35 µm (173–924 µm) at baseline and decreased to 279.16 µm (97 – 667) at visit 5. CSRT was 370.68 µm (202 – 1074) and decreased to 307.75 µm (168 – 590) at visit 5. Macular volume was reduced from 2.59 mm<sup>3</sup> (1.83 – 4.90) to 2.31 mm<sup>3</sup> (1.80 – 3.19) at visit 5. Intraocular inflammation was observed in one eye showing anterior chamber cells that resolved with topical corticosteroid treatment.</div></div><div><h3>Conclusions</h3><div>The results of the FAN (<strong>FA</strong>ricimab for <strong>N</strong>eovascular AMD) study indicate that faricimab improves structural outcomes in patients with recalcitrant fluid due to nAMD with no major complications observed.</div></div>","PeriodicalId":100071,"journal":{"name":"AJO International","volume":"1 4","pages":"Article 100074"},"PeriodicalIF":0.0000,"publicationDate":"2024-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AJO International","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2950253524000741","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose

This study presents real-world experiences and clinical outcomes of patients who switched to faricimab after prior treatment with other anti-vascular endothelial growth factor medication for patients with neovascular age-related macular degeneration (nAMD) in 2022.

Design

We evaluated all consecutive patients that received an intravitreal injection (IVI) with faricimab for nAMD and had complete follow-up visits after at least three IVI.

Methods

Functional and structural parameters including best-corrected visual acuity (BCVA, logMAR), foveal centre point (FCP, µm), central subfield retinal thickness (CSRT, µm) and macular volume (mm³) were evaluated after three (n = 71) and five (n = 57) faricimab injections with complete follow-up visits.

Results

We included 71 eyes of 63 patients. Mean BCVA at baseline was 0.49 logMAR (0 – 1.6) and did not change significantly after five faricimab injections (p = 0.33). Significant reductions were seen for FCP, CSRT and macular volume after the first five consecutive injections when compared to baseline (p < 0.0001 respectively). FCP was 388.35 µm (173–924 µm) at baseline and decreased to 279.16 µm (97 – 667) at visit 5. CSRT was 370.68 µm (202 – 1074) and decreased to 307.75 µm (168 – 590) at visit 5. Macular volume was reduced from 2.59 mm³ (1.83 – 4.90) to 2.31 mm³ (1.80 – 3.19) at visit 5. Intraocular inflammation was observed in one eye showing anterior chamber cells that resolved with topical corticosteroid treatment.

Conclusions

The results of the FAN (FAricimab for Neovascular AMD) study indicate that faricimab improves structural outcomes in patients with recalcitrant fluid due to nAMD with no major complications observed.

Abstract Image

查看原文本刊更多论文

玻璃体内法瑞西单抗治疗新生血管性黄斑病变的早期实际经验：FAN 研究

设计我们评估了所有接受过法尼单抗玻璃体内注射（IVI）治疗nAMD并在至少三次IVI后进行过完整随访的连续患者。方法评估了三次（n = 71）和五次（n = 57）法利单抗注射后的功能和结构参数，包括最佳矫正视力（BCVA，logMAR）、眼窝中心点（FCP，µm）、中央子场视网膜厚度（CSRT，µm）和黄斑体积（mm3），并进行了完整的随访。基线时的平均 BCVA 为 0.49 logMAR (0 - 1.6)，注射五次法尼单抗后无明显变化（p = 0.33）。连续注射五次后，FCP、CSRT 和黄斑体积与基线相比均有显著下降（分别为 p < 0.0001）。基线时的 FCP 为 388.35 微米（173-924 微米），在第 5 次注射时降至 279.16 微米（97-667）。CSRT 为 370.68 微米（202 - 1074），在第五次检查时降至 307.75 微米（168 - 590）。第 5 次检查时，黄斑体积从 2.59 立方毫米（1.83 - 4.90）降至 2.31 立方毫米（1.80 - 3.19）。结论 FAN（治疗新生血管性黄斑变性的法瑞西单抗）研究结果表明，法瑞西单抗可改善因 nAMD 引起的顽固性积液患者的结构性预后，且未观察到重大并发症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

AJO International

自引率

0.00%

发文量